Evidence map›Paper›PMID 36120550›Full record

ReviewFrontiers in molecular biosciences2022

Functions of regulators of G protein signaling 16 in immunity, inflammation, and other diseases.

Miaomiao Tian, Yan Ma, Tao Li, Nijin Wu, Jiaqi Li, Huimin Jia, Meizhu Yan, Wenwen Wang, Hongjun Bian, Xu Tan and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in molecular biosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. ε-Viniferin Rejuvenates Senescence viaPharmaceuticals (Basel, Switzerland) · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Dynamic regulation ofFrontiers in cell and developmental biology · 2025
    Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Miaomiao TianShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Yan MaZibo Central Hospital, Zibo, China.
Tao LiShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Nijin WuShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Jiaqi LiShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Huimin JiaShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Meizhu YanShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Wenwen WangShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Hongjun BianShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Xu TanShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Jianni QiShandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
Shandong First Medical University · CNShandong Provincial Hospital · CNCentral Hospital of Zibo · CNShandong Center for Disease Control and Prevention · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Regulators of G protein signaling (RGS) act as guanosine triphosphatase activating proteins to accelerate guanosine triphosphate hydrolysis of the G protein α subunit, leading to the termination of the G protein-coupled receptor (GPCR) downstream signaling pathway. RGS16, which is expressed in a number of cells and tissues, belongs to one of the small B/R4 subfamilies of RGS proteins and consists of a conserved RGS structural domain with short, disordered amino- and carboxy-terminal extensions and an α-helix that classically binds and de-activates heterotrimeric G proteins. However, with the deepening of research, it has been revealed that RGS16 protein not only regulates the classical GPCR pathway, but also affects immune, inflammatory, tumor and metabolic processes through other signaling pathways including the mitogen-activated protein kinase, phosphoinositide 3-kinase/protein kinase B, Ras homolog family member A and stromal cell-derived factor 1/C-X-C motif chemokine receptor 4 pathways. Additionally, the RGS16 protein may be involved in the Hepatitis B Virus -induced inflammatory response. Therefore, given the continuous expansion of knowledge regarding its role and mechanism, the structure, characteristics, regulatory mechanisms and known functions of the small RGS proteinRGS16 are reviewed in this paper to prepare for diagnosis, treatment, and prognostic evaluation of different diseases such as inflammation, tumor, and metabolic disorders and to better study its function in other diseases.

Indexed as

GPCRimmunityinflammationmetabolic disordersRGS16tumor

Identifiers

PMID36120550
PMCPMC9478547
OpenAlexW4294192423

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.